Additional Nitrogen Other Than Cyano Patents (Class 514/523)
-
Publication number: 20110245235Abstract: The present inventions provide combination therapies, kits, and methods for providing relief and/or for improving one or more symptoms associated with an auditory system disorder in a subject diagnosed with the auditory system disorder, comprising an effective amount of at least one pharmaceutical agent and at least one auditory system disorder device, as well as methods for using at least one pharmaceutical agent and/or at least one auditory system disorder device in the manufacture of said kits.Type: ApplicationFiled: October 9, 2009Publication date: October 6, 2011Inventors: Peter J. Hanley, Robert H. Frater, Arjun Goyal, Paul B. Davis
-
Publication number: 20110243937Abstract: The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.Type: ApplicationFiled: May 26, 2011Publication date: October 6, 2011Applicant: PHIGENIX, INC.Inventor: Carlton D. DONALD
-
Publication number: 20110230428Abstract: Certain chemical entities are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.Type: ApplicationFiled: July 22, 2009Publication date: September 22, 2011Inventors: John Wityak, Leticia M. Toledo-sherman, Celia Dominguez, Stephen Martin Courtney, Christopher John Yarnold, Paula C. De Aguiar Pena, Andreas Scheel, Dirk Winkler
-
Publication number: 20110196035Abstract: A composition and method for treatment of osteoarthritis is disclosed. The composition includes at least one soluble injectable biocompatible carrier having a viscosity within prescribed limits and an amount of a calcium-channel blocker chosen in relation to the viscosity of the carrier. The concentration of the calcium-channel blocker in the joint synovial fluid is controlled according to the invention whereby effective treatment of osteoarthritis is provided.Type: ApplicationFiled: January 26, 2011Publication date: August 11, 2011Inventors: Oleg V. Kolomytkin, Andrew A. Marino
-
Publication number: 20110196383Abstract: A method and chemical composition for modifying and dissolving atherosclerotic plaques formed in a patient's blood vessels is provided. A chemical composition comprising one or more of an organic substance, an inorganic substance, and a bioactive substance is administered at sites of the plaques. The chemical composition comprises one or more of d-limonene, propylene glycol, octanoic acid, 2-octane, glycerine, acetylsalicylic acid, acetic acid, omega-3 fatty acids, ethanol, methanol, ezetimibe, rosuvastatin, resveratrol, lactic acid, gluconic acid, chloroform, carbon disulfide, dichloromethane, toluene, lauryldimethyl hydroxysultaine, and any combination thereof. The chemical composition enables modification of plaques by altering their composition. The modification comprises partial dissolution, complete dissolution, or elimination of the plaques, and makes the plaques amenable to different forms of plaque treatment. The modified plaques are eliminated from the patient's body.Type: ApplicationFiled: April 15, 2011Publication date: August 11, 2011Inventors: Kusai Saadeldin Aziz, Gary Michael Saxton
-
Publication number: 20110182912Abstract: Various agents are described to denerve, modulate, or otherwise affect the renal nerves and other neural tissue. Also, various delivery devices are described to deliver an agent locally to the renal nerves. The delivery devices are positioned in the renal artery and penetrate into the wall of the renal artery to deliver the agent to the renal nerves. The delivery devices may be used to deliver the agent according to longitudinal position, radial position, and depth of the renal nerves relative to the renal artery. In addition, various methods are described to denervate, modulate, or otherwise affect the renal nerves and other neural tissue.Type: ApplicationFiled: January 26, 2011Publication date: July 28, 2011Inventors: Michael A. EVANS, Kondapavulur T. VENKATESWARA-RAO, Emily A. STEIN
-
Publication number: 20110166195Abstract: The present invention relates to an in-vitro method for the formation of megamitochondria in cells, wherein the cells are grown in a suitable fermentation medium acidulated with lactic acid to pH values between 5.3 and 6.7. The invention further concerns H+ ionophores, ionophores which catalyze the electroneutral exchange of K+ for H+ and inhibitors of actin polymerisation for the prevention or treatment of a disease in which inhibiting or reducing the formation of megamitochondria has a beneficial effect.Type: ApplicationFiled: June 19, 2009Publication date: July 7, 2011Applicant: UNIVERSITAT LEIPZIGInventor: Peter Seibel
-
Publication number: 20110110916Abstract: Provided is a method of treating or preventing a cardiomyopathy associated with activation of at least one kinase in the MAP kinase signaling pathway in heart tissue by providing to a subject an inhibitor of at least one kinase in the ERK signaling pathway or in the JNK signaling pathway, or both. In some embodiments, the cardiomyopathy is associated with one or more mutations in the LMNA gene, which encodes A-type nuclear lamins, or in the EMD gene, which encodes an inner nuclear membrane protein.Type: ApplicationFiled: November 1, 2010Publication date: May 12, 2011Inventors: Howard J. Worman, Antoine Muchir
-
Publication number: 20110077239Abstract: A medicament for the treatment of the phantom phenomena of acute tinnitus and/or phantom pain, a method for the production of such a medicament, and a method for the treatment of such phantom phenomenaType: ApplicationFiled: June 18, 2010Publication date: March 31, 2011Inventors: Marlies Knipper, Lukas Ruettiger, Bernhard Schick, Julia Dlugaiczyk
-
Publication number: 20110071104Abstract: A method and composition for treating osteoarthritis with ion-channel regulators is disclosed. The ion-channel regulators are used alone or in combination with other osteoarthritis treatment agents, including but not limited to injectable agents such as viscosupplements and steroids. A composition comprising one or more ion-channel regulator(s) and one or more osteoarthritis treatment agent(s) is also disclosed.Type: ApplicationFiled: June 21, 2010Publication date: March 24, 2011Inventor: David D. Waddell
-
Publication number: 20110038792Abstract: Dual suppression of the MAP kinase and PI3K/Akt pathways showed synergistic or greatly enhanced anti-melanoma cell effects, compared to suppression of a single pathway, including the inhibition of cell proliferation, transformation and invasion, induction of G0/G1 cell cycle arrest and, importantly, cell apoptosis. Remarkably, suppression of either pathway induces the expression of thyroid iodide-handling genes and dual suppression of the two pathways synergistically and robustly induces expression of these genes, accompanied by uptake of radioiodine in the cells. These genes include sodium/iodide symporter, thyroid-stimulating hormone receptor, thyroglobulin, thyroperoxidase, pendrin gene, thyroid transcription factors (e.g., TTF-1, TTF-2, PAX8) and other thyroid genes.Type: ApplicationFiled: February 5, 2009Publication date: February 17, 2011Applicant: THE JOHNS HOPKINS UNIVERSITYInventor: Michael Mingzhao Xing
-
Publication number: 20110028456Abstract: A pharmaceutical composition comprising a solid unit dosage form comprising: one or more of pharmaceutically active ingredients selected from valacyclovir, olanzapine, voriconazole, topotecan, artesunate, amodiaquine, guggulosterone, ramipril, telmisartan, tibolone, atorvastatin, simvastatin, amlodipine, ezetimibe, fenofibrate, tacrolimus, valgancyclovir, valsartan, clopidrogel, estradiol, trenbolone, efavirenz, metformin, pseudoephedrine, verapamil, felodipine, valproic acid/sodium valproate, mesalamine, hydrochlorothiazide, levosulpiride, nelfinavir, cefixime and cefpodoxime proxetil in combination with a water insoluble polymer and/or a water soluble polymer. Methods for making the pharmaceutical composition are also disclosed.Type: ApplicationFiled: January 12, 2009Publication date: February 3, 2011Applicant: CIPLA LIMITEDInventors: Amar Lulla, Geena Malhotra
-
Publication number: 20110009469Abstract: The present invention provides compositions and methods featuring microRNA polynucleotides for the diagnosis, treatment or prevention of neoplasia.Type: ApplicationFiled: December 5, 2008Publication date: January 13, 2011Applicant: The Johns Hopkins UniversityInventors: Joshua T. Mendell, Oliver Andrew Kent, Anirban Maitra
-
Publication number: 20100311742Abstract: The present invention provides methods of killing, inhibiting the growth, and/or inhibiting the reproduction of kine-toplastid or apicomplexan protozoan with tyrosine kinase inhibitors.Type: ApplicationFiled: November 21, 2007Publication date: December 9, 2010Applicant: University of Georgia Research Foundation, Inc.Inventor: Kojo Mensa-Wilmot
-
Publication number: 20100298200Abstract: The present invention relates to the field of therapeutic methods to screen for compounds on the basis of their ability to influence Wnt activity. The screening process is applied to both a physical library of a series of compounds and a virtual library of compounds that affect Wnt activity. In one aspect, the virtual screening process could be carried out where a permutational library of small peptides is substituted for the small organic molecules. The inventive methods may be used to empirically test for effects on Wnt activity and may also be applied to any pair of proteins involved in protein-protein interactions.Type: ApplicationFiled: May 22, 2009Publication date: November 25, 2010Inventors: Dakai Liu, Xiaofeng Li, Richard Jin, Yuaxin Liang, Wei Cheng, Riddhi Bhattacharyya, Guangrong Zhang
-
Publication number: 20100298374Abstract: Disclosed are nitrile derivatives and pharmaceutical compositions comprising nitrile derivatives. The pharmaceutical compositions comprise compounds of the formula I and the pharmaceutically acceptable salts of such compounds. Also disclosed are processes for the preparation of such compounds, intermediates used in the preparation of such compounds, and the uses of such compounds in treating hyperproliferative diseases, inflammatory diseases and viral and bacterial infections and inducing apoptosis in cancer cells.Type: ApplicationFiled: May 14, 2010Publication date: November 25, 2010Applicant: CELLCEUTIX CORPORATIONInventor: Krishna MENON
-
Publication number: 20100266503Abstract: A method of combating breast cancer in a mammalian individual, the method comprising administering to the individual an agent which reduces the function of the gamma secretase (GS) complex.Type: ApplicationFiled: April 7, 2008Publication date: October 21, 2010Inventors: Martin Slade, Raoul Charles Coombes
-
Publication number: 20100255001Abstract: The present invention relates to a method of treating hepatitis comprising administering a serotonin blocker, and the use of such blockers in said treatment and in the manufacture of medicaments for treating hepatitis.Type: ApplicationFiled: September 22, 2008Publication date: October 7, 2010Inventors: Karl Lang, Philipp Lang, Hans Hengartner, Rolf Zinkernagel, Panco Georgiev
-
Publication number: 20100239656Abstract: Compositions and methods for the treatment and diagnosis of cancer are disclosed.Type: ApplicationFiled: May 10, 2010Publication date: September 23, 2010Inventors: Igor Astsaturov, Erica A. Golemis, Ilya G. Serebriiskii, Louis M. Weiner
-
Publication number: 20100239666Abstract: The invention relates to a process for producing mouldings by injection moulding the steps in the process being a) melting and mixing of a (meth)acrylate copolymer composed of from 85 to 98% by weight of C1-C4-alkyl (meth)acrylates capable of free-radical polymerization and from 15 to 2% by weight of (meth)acrylate monomers having a quaternary ammonium group in the alkyl radical, with from 10 to 25% by weight of a plasticizer, and also from 10 to 50% by weight of a dryers [sic] and/or from 0.1 to 3% by weight of a release agent, and, where appropriate, with other conventional pharmaceutical additives or auxiliaries and/or with an active pharmaceutical ingredient, b) devolatilizing the mixture at temperatures of at least 120° C., thus reducing the content of the low-boiling constituents with a vapour pressure of at least 1.9 bar at 120° C. to not more than 0.5% by weight, and c) injecting the devolatilized mixture at a temperature of from 80 to 160° C.Type: ApplicationFiled: June 3, 2010Publication date: September 23, 2010Inventors: Hans-Ulrich Petereit, Thomas Beckert, Manfred Assmus, Wemer Hoess, Wolfgang Fuchs, Hartmut Schikowsky
-
Patent number: 7767710Abstract: A method and composition for treating osteoarthritis with ion-channel regulators is disclosed. The ion-channel regulators are used alone or in combination with other osteoarthritis treatment agents, including but not limited to injectable agents such as viscosupplements and steroids. A composition comprising one or more ion-channel regulator(s) and one or more osteoarthritis treatment agent(s) is also disclosed.Type: GrantFiled: May 25, 2005Date of Patent: August 3, 2010Assignee: Calosyn Pharma, Inc.Inventor: David D. Waddell
-
Publication number: 20100152248Abstract: The invention relates to the use of at least on inhibitor selected from the group consisting of raf-, protein kinase C(PKC)-, MEK1/2-, or ERK1/2-inhibitors, for the manufacturing of a medicament to be administrated from 1 up to 12 hours after initiation of an ischemic disease.Type: ApplicationFiled: March 25, 2008Publication date: June 17, 2010Applicant: Pronas Pharma ABInventors: Lars Edvinsson, Saema Ansar
-
Publication number: 20100137431Abstract: The invention consists in that substances acting as cascade inhibitors of the Raf/MEK/ERK signaling pathway, in particular MEK inhibitors, are used for the production of a drug for the preventive and antiviral therapy against DNA and RNA viruses, in particular against intranuclear-replicating negative strand RNA viruses, for instance influenza or Borna disease viruses.Type: ApplicationFiled: May 21, 2009Publication date: June 3, 2010Inventors: Stephan Ludwig, Stephan Pleschka
-
Patent number: 7723384Abstract: The invention relates to novel keto lactam compounds, hydrogenated derivatives and tautomers thereof. These compounds have valuable therapeutic properties and are particularly suited for treating diseases that respond to the modulation of the dopamine D3 receptor.Type: GrantFiled: December 10, 2004Date of Patent: May 25, 2010Assignee: Abbott GmbH & Co. KG.Inventors: Wilfried Lubisch, Andreas Haupt, Wilfried Braje, Herve Geneste
-
Publication number: 20100099741Abstract: Described herein are methods for identification of alternative safe molecular targets and novel regulators in complex molecular networks using a novel fault diagnosis engineering approach. For example, in this invention we claim new molecular targets that could be effectively targeted for changing the activity of CREB, and therefore for treatment of learning and memory related disorders. Learning and memory dysfunction is a major clinical manifestation of a number of human disorders, such as Alzheimer Disease (AD), schizophrenia, dementias, autism, etc. More specifically, we claim that composition and compounds that can target the activity of L AND/OR P/Q-, N-type calcium channels, G?i, G??, PP2A and CaMKII and IV are effective therapeutics for the treatment of disorders manifested by learning and memory dysfunction.Type: ApplicationFiled: October 20, 2009Publication date: April 22, 2010Inventor: Effat Emamian
-
Publication number: 20080275114Abstract: Compounds of formula (I), in which R1 and R2 are independently a substituted phenyl group, where the substituents are as defined in the claims and with the proviso that at least one of the substituents is a cyano, carboxy or (C1-4)alkoxycarbonyl group, are inhibitors of CCR9 activity useful for therapeutic treatment, particularly of irritable bowel disease.Type: ApplicationFiled: December 22, 2006Publication date: November 6, 2008Inventors: Jose M. Carballido Herrera, Herbert Jaksche, Philipp Lehr, Gudrun Werner, Anthony Winiski
-
Patent number: 7442718Abstract: The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.Type: GrantFiled: July 2, 2003Date of Patent: October 28, 2008Assignee: Vertex Pharmaceuticals IncorporatedInventors: Michael R Hale, Christopher T Baker, Timothy A Stammers, Ronald G Sherrill, Andrew Spaltenstein, Eric S Furfine, Francois Maltais, Clarence W Andrews, III, John F Miller, Vicente Samano
-
Patent number: 7307101Abstract: A method for treating cerebral vascular diseases in a human or non-human animal is disclosed. The method involves inhibiting 20-HETE synthesizing enzyme activity sufficiently to increase or prevent a decrease in cerebral blood flow in the human or non-human animal.Type: GrantFiled: September 6, 2001Date of Patent: December 11, 2007Assignees: MCW Research Foundation, Inc., Taisho Pharmaceutical Co., Ltd.Inventors: Richard J. Roman, David R. Harder, Noriyuki Miyata, Masakazu Sato, Kazuya Kameo, Shigeru Okuyama
-
Patent number: 7217737Abstract: The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers characterized by over-activity or inappropriate activity HER2 or EGFR.Type: GrantFiled: June 25, 2003Date of Patent: May 15, 2007Assignees: Yissum Research and Development Company of the Hebrew University of Jerusalem, Sugen, Inc.Inventors: Hui Chen, Aviv Gazit, Alexander Levitzki, Klaus Peter Hirth, Elaina Mann, Peng Cho Tang, Laura K. Shawver, Jianming Tsai
-
Patent number: 7102026Abstract: The present invention relates to a new process for the synthesis of racemic and optically active bicalutamide starting from ethyl pyruvate and methyl methacrylate. The present invention discloses processes of preparing bicalutamide intermediates including ethyl-[2-{4-fluorophenyl sulfone}]-2-hydroxy propionate, 1,2-epoxy-2-methyl propionate and 2-hydrox-2-methyl-3-(4-fluorophenylthio) propionic acid. The present invention further discloses micronized rac-bicalutamide and the preparation thereof. The present invention further discloses a new process for the isolation and purification of racemic and optically active bicalutamide.Type: GrantFiled: June 25, 2003Date of Patent: September 5, 2006Assignee: TEVA Gyógyszergyár Zártkörüen Müködö RészvénytársaságInventors: Ben-Zion Dolitzky, Ofer Reany, Jenny Shammai
-
Patent number: 7084280Abstract: The invention relates to benzotriazol-1-yl-aminoacetonitrile compounds and optionally the enantiomers thereof. The active ingredients have advantageous pesticidal properties. They are especially suitable for controlling parasites on warm-blooded animals.Type: GrantFiled: September 10, 2003Date of Patent: August 1, 2006Inventors: Pierre Ducray, Thomas Goebel, Noelle Gauvry
-
Patent number: 7034045Abstract: The present invention provides certain monofluoroalkyl derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.Type: GrantFiled: April 17, 2000Date of Patent: April 25, 2006Assignee: Eli Lilly and CompanyInventors: David Michael Bender, Buddy Eugene Cantrell, Andrew Hendley Fray, Winton Dennis Jones, William David Miller, David Mitchell, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
-
Patent number: 7012095Abstract: Novel styrylacrylonitrile compounds which are useful in treating a variety of cell proliferative disorders such as cancer are disclosed. The compounds are of Formula (I).Type: GrantFiled: April 12, 2001Date of Patent: March 14, 2006Assignee: HSC Research and Development LimitedInventors: Chaim M. Roifman, Thomas Grunberger, Olga Rounova, Demin Peter, Nigel Sharfe
-
Patent number: 6946426Abstract: Provided is a method of formulating hydrophobic pesticides comprising emulsifying an aqueous phase and a water-immiscible phase to form a formulation; wherein the aqueous phase is comprised of water and optionally a freeze/thaw agent, one or more emulsifiers, or combinations thereof, and the water-immiscible phase comprises the hydrophobic pesticide and one or more emulsifiers.Type: GrantFiled: March 21, 2001Date of Patent: September 20, 2005Assignee: FMC CorporationInventors: Timothy M. Martin, MaryEllen Lavin
-
Patent number: 6908925Abstract: A regime or regimen for loosening/slackening and/or relaxing cutaneous and/or subcutaneous human skin tissue, advantageously for cosmetically/therapeutically treating skin wrinkles and fine lines, comprises administering to a candidate subject in need of such treatment, a thus-effective amount of at least one inhibitor of at least one calcium channel.Type: GrantFiled: October 19, 2001Date of Patent: June 21, 2005Assignee: L'OrealInventors: Lionel Breton, Isabelle Nonotte
-
Patent number: 6852328Abstract: A method and device are disclosed which prevents the decay and deterioration of wooden objects caused by pests by using a controlled release device. This controlled release device utilizes polymers which incorporate pesticides. In the disclosed method, the controlled release device is placed in contact with the wood of the wooden object. The pesticide is gradually released from the device and absorbed into the wood structure. The pesticide absorbed by the wood creates a barrier or an exclusion zone to penetration by inserts. The controlled release device maintains a minimal effective level of pesticide in the barrier or exclusion zone for a predetermined period of time.Type: GrantFiled: December 20, 1996Date of Patent: February 8, 2005Assignee: Battelle Memorial Institute K1-53Inventors: Peter Van Voris, Dominic A. Cataldo, Frederick G. Burton
-
Patent number: 6849661Abstract: The present invention is directed to methods of treating, preventing, and/or managing abnormal increases in gastrointestinal motility, and intestinal conditions that cause the same. Such conditions include, but are not limited to, irritable bowel syndrome (IBS), infectious diseases of the small and large intestines, and symptoms of any of the foregoing. In particular, the present invention discloses methods of using enriched (R)-verapamil, as well as compositions and formulations containing the same.Type: GrantFiled: November 15, 2002Date of Patent: February 1, 2005Assignee: AGI Therapeutics, Ltd.Inventors: John Kelly, John Devane, Ted G. Dinan, P.W. Napoleon Keeling
-
Publication number: 20040266867Abstract: The invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 is H, chlorine, or bromine; R2 is electron attractive groups selected from the group consisting of CF3, CN, fluorine, CH3SO3, CF3SO3, and NO2; R3 is linear or branched alkyl having 1 to 10 carbon atoms, linear or branched alkoxyalkyl having 2 to 10 carbon atoms, aliphatic alcohol having 1 to 10 carbon atoms, or cycloalkyl having 3 to 6 carbon atoms. The invention also relates to methods for preparing the said compounds and the composition comprising the same. The compounds of the present invention have the effect of &bgr;2-receptor agonist and can be used for the treatment of asthma and bronchitis.Type: ApplicationFiled: August 16, 2004Publication date: December 30, 2004Inventors: Maosheng Cheng, Li Pan, Lie Ji, Li Zhang, Jianmin Shen, Guilan Song, Zhiging Li
-
Publication number: 20040242656Abstract: Compounds of formula (I) 1Type: ApplicationFiled: June 28, 2004Publication date: December 2, 2004Inventors: John Walter Liebeschuetz, Christopher William Murray, Stephen Clinton Young, Nicholas Paul Camp, Stuart Donald Jones, William Alexander Wylie, John Joseph Masters, Michael Robert Wiley, Scott Martin Sheehan, David Birenbaum Engel, Brian Morgan Watson
-
Publication number: 20040229923Abstract: A method for resolving enantiomers of a compound containing the structure of the formula: 1Type: ApplicationFiled: June 16, 2004Publication date: November 18, 2004Inventors: Glenn E. Wilcox, Mark E. Flanagan, Michael J. Munchhof, Ton Vries, Christian Koecher
-
Publication number: 20040214889Abstract: Novel methods of treating bone diseases or disorders are provided.Type: ApplicationFiled: May 24, 2004Publication date: October 28, 2004Applicants: SmithKline Beecham Corporation, NPS Pharmaceuticals, Inc.Inventors: Maxine Gowen, Larry J. Suva, John Fox, George B. Stroup, Edward F. Nemeth
-
Patent number: 6800659Abstract: Novel styrylacrylonitrile compounds which are useful in treating a variety of cell proliferative disorders such as cancer are disclosed.Type: GrantFiled: April 12, 2001Date of Patent: October 5, 2004Assignee: HSC Research and Development Limited PartnershipInventors: Chaim M. Roifman, Thomas Grunberger, Olga Rounova, Demin Peter, Nigel Sharfe
-
Publication number: 20040171654Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.Type: ApplicationFiled: November 17, 2003Publication date: September 2, 2004Inventors: Solomon Ugashe, Zheng Wei, J. J. Wright, Andrew Pennell
-
Patent number: 6780508Abstract: Carriers for use in the preparation of mixtures for inhalation powders intended for pulmonary administration of micronized drugs by means of a dry powder inhaler and the method for their preparation are described.Type: GrantFiled: April 16, 2002Date of Patent: August 24, 2004Assignee: Chiesi Farmaceutici S.p.A.Inventors: Giovanni Caponetti, Pier Luigi Catellani, Ruggero Bettini, Paolo Colombo, Paolo Ventura
-
Publication number: 20040157818Abstract: To provide novel nitrogen-containing compounds having antagonism to CXCR4 and remedies for disease, such as rheumatism, cancer metastasis, etc., based on the CXCR4 antagonism.Type: ApplicationFiled: January 16, 2004Publication date: August 12, 2004Inventors: Mikiro Yanaka, Toru Yamazaki, Kenji Bannai, Kunitaka Hirose
-
Publication number: 20040147515Abstract: The object of the present patent application are 3-aminophenol derivatives of formula (I) or the physiologically compatible, water-soluble salts thereof 1Type: ApplicationFiled: November 24, 2003Publication date: July 29, 2004Inventors: Gisela Umbricht, Franco Jose Rosato, Hans-Juergen Braun
-
Publication number: 20040138301Abstract: This invention relates to chemical uncouplers with a broader safety window making the use of them in treating obesity and, consequently, in the treatment of obesity related diseases and conditions such as atherosclerosis, hypertension, diabetes, especially type 2 diabetes (NIDDM (non-insulin dependent diabetes mellitus)), impaired glucose tolerance, dyslipidemia, coronary heart disease, gallbladder disease, osteoarthritis and various types of cancer such as endometrial, breast, prostate and colon cancers and the risk for premature death as well as other conditions, such as diseases and disorders, which conditions are improved by an increase in mitochondrial respiration, more attractive.Type: ApplicationFiled: October 31, 2003Publication date: July 15, 2004Inventors: Birgit Sehested Hansen, Thomas Kruse Hansen, Soren Tullin, Morten Colding-Jorgensen
-
Publication number: 20040122058Abstract: The present invention relates to the use of specific compounds for the treatment and/or prophylaxis of inflammatory conditions. Furthermore, the present invention relates to the use of inhibitors for treating viral infections, particularly to the use of MEK inhibitors, especially MEKI inhibitors, for prophylaxis and/or treatment of virally induced hemorrhagic fever and/or hemorrhagic shock syndromes, for the treatment of virally induced TNF-∝ mediated diseases, and for regulating and/or inhibiting of virally induced TNF-∝ production. Furthermore, methods for preventing and/or treating of virally induced hemonrhagic fevers and/or hemorrhagic shock syndromes, for regulating and/or inhibiting virally induced TNF-∝ production, and for the treatment of virally induced TNF-÷ medicated diseases are disclosed together with pharmaccutical compositions useful within said methods.Type: ApplicationFiled: January 30, 2004Publication date: June 24, 2004Inventors: Dorian Bevec, Ute Stroher, Hans-Dieter Klenk, Christian Wallasch
-
Publication number: 20040087583Abstract: This invention relates generally to amino-thio-acrylonitriles of formula Ia or Ib: 1Type: ApplicationFiled: October 30, 2003Publication date: May 6, 2004Inventor: Frank Worden Hobbs
-
Publication number: 20040072803Abstract: Novel styrylacrylonitrile compounds which are useful in treating a variety of cell proliferative disorders such as cancer are disclosed. The compounds are of Formula (1).Type: ApplicationFiled: October 27, 2003Publication date: April 15, 2004Inventors: Chaim M. Roifman, Thomas Grunberger, Olga Rounova, Demin Peter, Nigel Sharfe